论文部分内容阅读
2015年8月,国务院印发《关于改革药品医疗器械审评审批制度的意见》,意在解决长期以来形成的药品注册积压、新药上市慢、制药行业低水平重复、创新能力不足等突出问题。目前,改革不断推进,进展顺利。2017年6月26日,十二届全国人大常委会第二十八次会议举行分组会议,审议国务院关于药品管理工作情况的报告、全国人大常委会执法检查组关于药品管理法实施情况的报告。与会人员指出,我国药品审评审批体制改革不断深
In August 2015, the State Council issued the Opinions on Reforming the Examination and Approval System of Medical Devices for Medical Devices, which aims to solve the outstanding problems of long-term drug registration, slow listing of new drugs, low repetition of the pharmaceutical industry, and lack of innovation capability. At present, the reform has been continuously promoted and progress has been proceeding smoothly. On June 26, 2017, the 28th meeting of the Standing Committee of the 12th National People’s Congress held a breakout meeting to review the State Council’s report on the work on drug administration and the report on the implementation of the Drug Administration Law by the Law Enforcement Inspection Section of the NPC Standing Committee. Participants pointed out that China’s drug review and approval system reform deepening